Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathy
Open Access
- 4 February 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 11 (2) , e305
Abstract
Background: Diabetic nephropathy (DN), one of the major complications of diabetes, is characterized by albuminuria, glomerulosclerosis, and progressive loss of renal function. Loss of TIMP3, an Extracellular Matrix bound protein affecting both inflammation and fibrosis, is a hallmark of DN in human subjects and mouse models.Methods: This study was designed to provide evidences that the modulation of the system involving TIMP3 and its target A Disintegrin And Metalloproteinase 17 (ADAM17), may rescue kidney pathology in diabetic mice. Mice with cell‐targeted overexpression of TIMP3 in myeloid cells (MacT3), podocyte‐specific ADAM17 knockout mice (∆PodA17), and DBA/2J mice, were rendered diabetic at 8 weeks of age with a low‐dose streptozotocin protocol. DBA/2J mice were administered new peptides based on the human TIMP3 N‐terminal domain, specifically conjugated with G3C12, a carrier peptide highly selective and efficient for transport to the kidney. Twelve weeks after Streptozotocin injections, 24‐hour albuminuria was determined by ELISA, kidney morphometry was analyzed by periodic acid‐shift staining, and Real Time‐PCR and western blot analysis were performed on mRNA and protein extracted from kidney cortex.Results: Our results showed that both genetic modifications and peptides treatment positively affect renal function and structure in diabetic mice, as indicated by a significant and consistent decline in albuminuria along with reduction in glomerular lesions, as indicated by reduced mesangial expansion and glomerular hypertrophy, decreased deposition of extracellular matrix in the mesangium, diminished protein expression of the NADPH oxidases 4 (NOX4), and the improvement of podocyte structural markers such as WT1, nephrin, and podocin. Moreover, the positive effects were exerted through a mechanism independent from glycemic control.Conclusions: In diabetic mice the targeting of TIMP3 system improved kidney structure and function, representing a valid approach to develop new avenues to treat this severe complication of diabetes.Keywords
Funding Information
- European Association for the Study of Diabetes
- Juvenile Diabetes Research Foundation International (JDRF/2‐SRA‐2014‐262)
This publication has 62 references indexed in Scilit:
- Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplayEMBO Molecular Medicine, 2013
- Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 DiabetesJournal of the American Society of Nephrology, 2012
- Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 DiabetesJournal of the American Society of Nephrology, 2012
- TIMP3 Overexpression in Macrophages Protects From Insulin Resistance, Adipose Inflammation, and Nonalcoholic Fatty Liver Disease in MiceDiabetes, 2012
- Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritisNature Medicine, 2011
- Transcriptome Analysis of Human Diabetic Kidney DiseaseDiabetes, 2011
- Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in PericytesCirculation Research, 2010
- Simultaneous Transforming Growth Factor β-Tumor Necrosis Factor Activation and Cross-talk Cause Aberrant Remodeling Response and Myocardial Fibrosis in Timp3-deficient HeartJournal of Biological Chemistry, 2009
- Loss of TIMP3 Enhances Interstitial Nephritis and FibrosisJournal of the American Society of Nephrology, 2009
- Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruliKidney International, 1999